New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS
- Written by PR Newswire
![]() |
- Minjuvi® (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination regimen listed on the Pharmaceutical Benefits Scheme (PBS) for adults with relapsed or refractory follicular lymphoma (R/R FL) (Grade 1-3a).[1],[2]
- In the pivotal Phase 3 inMIND...
Read more: New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS















